Biosimilars-United States Market Status and Trend Report 2013-2023

Date: February 21, 2018
Pages: 140
Price:
US$ 3,480.00
Publisher: MIReports Co., Limited
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B9140704874EN
Leaflet:

Download PDF Leaflet

Biosimilars-United States Market Status and Trend Report 2013-2023
Report Summary

Biosimilars-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biosimilars industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Biosimilars 2013-2017, and development forecast 2018-2023
Main market players of Biosimilars in United States, with company and product introduction, position in the Biosimilars market
Market status and development trend of Biosimilars by types and applications
Cost and profit status of Biosimilars, and marketing status
Market growth drivers and challenges

The report segments the United States Biosimilars market as:

United States Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England
The Middle Atlantic
The Midwest
The West
The South
Southwest

United States Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Antibody
Hormone
Growth Factors

United States Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Tumor
Diabetes
Cardiovascular
Hemophilia
Other

United States Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biosimilars Sales Volume, Revenue, Price and Gross Margin):

Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

CHAPTER 1 OVERVIEW OF BIOSIMILARS

1.1 Definition of Biosimilars in This Report
1.2 Commercial Types of Biosimilars
  1.2.1 Antibody
  1.2.2 Hormone
  1.2.3 Growth Factors
1.3 Downstream Application of Biosimilars
  1.3.1 Tumor
  1.3.2 Diabetes
  1.3.3 Cardiovascular
  1.3.4 Hemophilia
  1.3.5 Other
1.4 Development History of Biosimilars
1.5 Market Status and Trend of Biosimilars 2013-2023
  1.5.1 United States Biosimilars Market Status and Trend 2013-2023
  1.5.2 Regional Biosimilars Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Biosimilars in United States 2013-2017
2.2 Consumption Market of Biosimilars in United States by Regions
  2.2.1 Consumption Volume of Biosimilars in United States by Regions
  2.2.2 Revenue of Biosimilars in United States by Regions
2.3 Market Analysis of Biosimilars in United States by Regions
  2.3.1 Market Analysis of Biosimilars in New England 2013-2017
  2.3.2 Market Analysis of Biosimilars in The Middle Atlantic 2013-2017
  2.3.3 Market Analysis of Biosimilars in The Midwest 2013-2017
  2.3.4 Market Analysis of Biosimilars in The West 2013-2017
  2.3.5 Market Analysis of Biosimilars in The South 2013-2017
  2.3.6 Market Analysis of Biosimilars in Southwest 2013-2017
2.4 Market Development Forecast of Biosimilars in United States 2018-2023
  2.4.1 Market Development Forecast of Biosimilars in United States 2018-2023
  2.4.2 Market Development Forecast of Biosimilars by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types
  3.1.1 Consumption Volume of Biosimilars in United States by Types
  3.1.2 Revenue of Biosimilars in United States by Types
3.2 United States Market Status by Types in Major Countries
  3.2.1 Market Status by Types in New England
  3.2.2 Market Status by Types in The Middle Atlantic
  3.2.3 Market Status by Types in The Midwest
  3.2.4 Market Status by Types in The West
  3.2.5 Market Status by Types in The South
  3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Biosimilars in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Biosimilars in United States by Downstream Industry
4.2 Demand Volume of Biosimilars by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Biosimilars by Downstream Industry in New England
  4.2.2 Demand Volume of Biosimilars by Downstream Industry in The Middle Atlantic
  4.2.3 Demand Volume of Biosimilars by Downstream Industry in The Midwest
  4.2.4 Demand Volume of Biosimilars by Downstream Industry in The West
  4.2.5 Demand Volume of Biosimilars by Downstream Industry in The South
  4.2.6 Demand Volume of Biosimilars by Downstream Industry in Southwest
4.3 Market Forecast of Biosimilars in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILARS

5.1 United States Economy Situation and Trend Overview
5.2 Biosimilars Downstream Industry Situation and Trend Overview

CHAPTER 6 BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Biosimilars in United States by Major Players
6.2 Revenue of Biosimilars in United States by Major Players
6.3 Basic Information of Biosimilars by Major Players
  6.3.1 Headquarters Location and Established Time of Biosimilars Major Players
  6.3.2 Employees and Revenue Level of Biosimilars Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Roche
  7.1.1 Company profile
  7.1.2 Representative Biosimilars Product
  7.1.3 Biosimilars Sales, Revenue, Price and Gross Margin of Roche
7.2 Amgen
  7.2.1 Company profile
  7.2.2 Representative Biosimilars Product
  7.2.3 Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
7.3 AbbVie
  7.3.1 Company profile
  7.3.2 Representative Biosimilars Product
  7.3.3 Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
7.4 Sanofi-Aventis
  7.4.1 Company profile
  7.4.2 Representative Biosimilars Product
  7.4.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.5 Johnson & Johnson
  7.5.1 Company profile
  7.5.2 Representative Biosimilars Product
  7.5.3 Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.6 Pfizer
  7.6.1 Company profile
  7.6.2 Representative Biosimilars Product
  7.6.3 Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
7.7 Novo Nordisk
  7.7.1 Company profile
  7.7.2 Representative Biosimilars Product
  7.7.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eli Lilly
  7.8.1 Company profile
  7.8.2 Representative Biosimilars Product
  7.8.3 Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
7.9 Novartis
  7.9.1 Company profile
  7.9.2 Representative Biosimilars Product
  7.9.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
7.10 Merck
  7.10.1 Company profile
  7.10.2 Representative Biosimilars Product
  7.10.3 Biosimilars Sales, Revenue, Price and Gross Margin of Merck
7.11 Sun
  7.11.1 Company profile
  7.11.2 Representative Biosimilars Product
  7.11.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sun
7.12 3sbio
  7.12.1 Company profile
  7.12.2 Representative Biosimilars Product
  7.12.3 Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
7.13 Changchun High Tech
  7.13.1 Company profile
  7.13.2 Representative Biosimilars Product
  7.13.3 Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech
7.14 CP Guojian
  7.14.1 Company profile
  7.14.2 Representative Biosimilars Product
  7.14.3 Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian
7.15 Biotech
  7.15.1 Company profile
  7.15.2 Representative Biosimilars Product
  7.15.3 Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
7.16 Gelgen
7.17 Innovent
7.18 Dong Bao
7.19 Ganlee
7.20 United Laboratories

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILARS

8.1 Industry Chain of Biosimilars
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILARS

9.1 Cost Structure Analysis of Biosimilars
9.2 Raw Materials Cost Analysis of Biosimilars
9.3 Labor Cost Analysis of Biosimilars
9.4 Manufacturing Expenses Analysis of Biosimilars

CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOSIMILARS

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference
Skip to top


Ask Your Question

Biosimilars-United States Market Status and Trend Report 2013-2023
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: